المؤلفون: A. Karateev E., E. Nasonov L., V. Ivashkin T., A. Martynov I., N. Yakhno N., G. Arutyunov P., L. Alekseeva I., G. Abuzarova R., M. Evseev A., M. Kukushkin L., S. Kopenkin S., A. Lila M., T. Lapina L., D. Novikova S., T. Popkova V., A. Rebrov P., K. Skorobogatykh V., N. Chichasova V., А. Каратеев Е., Е. Насонов Л., В. Ивашкин Т., А. Мартынов И., Н. Яхно Н., Г. Арутюнов П., Л. Алексеева И., Г. Абузарова Р., М. Евсеев А., М. Кукушкин Л., С. Копенкин С., А. Лила М., Т. Лапина Л., Д. Новикова С., Т. Попкова В., А. Ребров П., К. Скоробогатых В., Н. Чичасова В.

المصدر: Rheumatology Science and Practice; Vol 56 (2018): приложение 1; 1-29 ; Научно-практическая ревматология; Vol 56 (2018): приложение 1; 1-29 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20180

مصطلحات موضوعية: clinical guidelines, nonsteroidal anti-inflammatory drugs, efficacy, safety, NSAID gastropathy, NSAID enteropathy, cardiovascular events, nephrotoxicity, hepatotoxic reactions, клинические рекомендации, нестероидные противовоспалительные препараты, эффективность, безопасность, НПВП-гастропатия, НПВП-энтеропатия, кардиоваскулярные осложнения, нефротоксичность, гепатотоксические реакции

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2536/1691; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65 [Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65 (In Russ.)]. doi:10.14412/1995-4484-2016-247-265; Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi:10.1016/S0140-6736(15)61340-X. Epub 2015 Aug 28.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)]. ISBN 978-5-9704-4261-6.; Здравоохранение в России. 2017: Статистический сборник. Москва: Росстат; 2017. 170 с. [Zdravookhranenie v Rossii. 2017: Statisticheskii sbornik [Public health in Russia. 2017: Statistical Digest]. Moscow: Rosstat; 2017. 170 p. (In Russ.)]. ISBN 978-5-89476-448-1. http://www.gks.ru; Доступно по ссылке: https://www.iqvia.com/our-customers/pharmaceutical-manufacturers [Available from: https://www.iqvia.com/ our-customers/pharmaceutical-manufacturers].; Шостак НА, Рябкова АА, Савельев ВС, Малярова ЛН. Желудочно-кишечное кровотечение как осложнение гастропатий, связанных с приемом нестероидных противовоспалительных препаратов. Терапевтический архив. 2003;(5):70-4 [Shostak NA, Ryabkova AA, Savel'ev VS, Malyarova LN. Gastrointestinal bleeding as a complication of gastropathy associated with use of nonsteroidal antiinflammatory drugs. Terapevticheskii Arkhiv. 2003;(5):70-4 (In Russ.)].; Евсеев МА. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Русский медицинский журнал. 2006;(15):1099-107 [Evseev MA. NSAID-induced gastroduodenal ulcer complicated by bleeding. Russkii Meditsinskii Zhurnal. 2006;(15):1099-107 (In Russ.)].; Гельфанд БР, Проценко ДН, Бабаянц АВ, Каратеев АЕ. Острые кровотечения из верхних отделов желудочно-кишечного тракта: от эпидемиологии до формирования концепции консервативной терапии. Инфекции в хирургии. 2013;(4):11-7 [Gel'fand BR, Protsenko DN, Babayants AV, Karateev AE. Severe bleeding from the upper parts of the gastrointestinal tract: from epidemiology to the formation of the concept of conservative therapy. Infektsii v Khirurgii. 2013;(4):11-7 (In Russ.)].; Jafar W, Jafar AJN, Sharma A. Upper gastrointestinal haemorrhage: an update. Frontline Gastroenterol. 2016 Jan;7(1):32-40. doi:10.1136/flgastro-2014-100492. Epub 2014 Oct 10.; Del Piano M, Bianco MA, Cipolletta L, et al. The «Prometeo» study: online collection of clinical data and outcome of Italian patients with acute nonvariceal upper gastrointestinal bleeding. J Clin Gastroenterol. 2013 Apr;47(4):e33-7. doi:10.1097/MCG. 0b013e3182617dcc; Nagasue T, Nakamura S, Kochi S, et al. Time trends of the impact of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs on peptic ulcer bleeding in Japanese patients. Digestion. 2015;91(1):37-41. doi:10.1159/000368810. Epub 2015 Jan 20.; Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi:10.18433/J3VW2F; Каратеев АЕ, Насонов ЕЛ, Яхно НН. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi:10.14412/1996-7012-2015-1-4-23; Насонов ЕЛ, Ивашкин ВТ, Яхно НН и др. Проект Национальных клинических рекомендаций (основные положения) Ассоциации ревматологов России, Российской гастроэнтерологической ассоциации, Российского общества по изучению боли «Рациональное использование нестероидных противовоспалительных препаратов» (По результатам совещания группы экспертов, г. Москва, 01.04.2017). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):69-75 [Nasonov EL, Ivashkin VT, Yakhno NN, et al. Draft National Clinical Recommendations (main provisions) of the Association of Rheumatologists of Russia, the Russian Gastroenterological Association, the Russian Society for the Study of Pain «Rational Use of Non-steroidal Anti-Inflammatory Drugs» (Based on the results of a meeting of the expert group, Moscow, April 1, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(5):69-75 (In Russ.)]. doi:10.22416/1382-4376-2017-27-5-69-75; Доступно по ссылке: http://www.grls.rosminzdrav.ru/ [Available from: http://www.grls.rosminzdrav.ru/].; Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004 Oct 15;51(5):746-54. doi:10.1002/art.20698; Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11): 1-278, iii. doi:10.3310/hta12110; Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012;6:6-20. doi:10.2174/1874312901206010006. Epub 2012 Apr 3.; Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, doubleblind, controlled study. Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.; Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi:10.1002/14651858.CD000396.pub3; Puljak L, Marin A, Vrdoljak D, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5:CD009865. doi:10.1002/14651858.CD009865.pub2; Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6:CD012095. doi:10.1002/14651858.CD012095.pub2; Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;10:CD004233. doi:10.1002/14651858. CD004233.pub4; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017 Jul 8;390(10090):e21-e33. doi:10.1016/S0140-6736(17)31744-0; Combe B, Velicitat P, Garzon N, Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001 Mar;50 Suppl 1:S10-6.; Neighbor ML, Puntillo KA. Intramuscular ketorolac vs oral ibuprofen in emergency department patients with acute pain. Acad Emerg Med. 1998 Feb;5(2):118-22. doi:10.1111/j.1553-2712.1998.tb02595.x; Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995 Dec;26(6):682-6. doi:10.1016/S0196-0644(95)70037-4; Wright JM, Price SD, Watson WA. NSAID use and efficacy in the emergency department: single doses of oral ibuprofen versus intramuscular ketorolac. Ann Pharmacother. 1994 Mar;28(3):309-12. doi:10.1177/106002809402800301; Dougados M, Listrat V, Duchesne L, Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic. 1992 Nov 30;59(11):769-73.; Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71-9. doi:10.1111/j.1399-6576.1998.tb05083.x; Motov S, Yasavolian M, Likourezos A, et al. Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2017 Aug;70(2):177-84. doi:10.1016/j.annemergmed.2016.10.014. Epub 2016 Dec 16.; Fraquelli M, Casazza G, Conte D, Colli A. Non-steroid antiinflammatory drugs for biliary colic. Cochrane Database Syst Rev. 2016 Sep 9;9:CD006390. doi:10.1002/14651858.CD006390.pub2 [Epub ahead of print].; Pathan SA, Mitra B, Cameron PA. A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Antiinflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic. Eur Urol. 2018 Apr;73(4):583-95. doi:10.1016/j.eururo.2017.11.001. Epub 2017 Nov 22.; Machado GC, Maher CG, Ferreira PH, et al. Non-steroidal antiinflammatory drugs for spinal pain: a systematic review and metaanalysis. Ann Rheum Dis. 2017 Jul;76(7):1269-78. doi:10.1136/annrheumdis-2016-210597. Epub 2017 Feb 2.; Rossi L, Conen D. Intramuscular injections – an outdated form of administration? 6 cases of Staphylococcus aureus sepsis following intramuscular injections. Schweiz Med Wochenschr. 1995 Aug 8;125(31-32):1477-82 (In Germ.).; Rotman-Pikielny P, Levy Y, Eyal A, Shoenfeld Y. Pyomyositis or «injectiositis» – Staphylococcus aureus multiple abscesses following intramuscular injections. Isr Med Assoc J. 2003 Apr;5(4):295-6.; Frick S, Cerny A. Necrotizing fasciitis due to Streptococcus pneumoniae after intramuscular injection of nonsteroidal anti-inflammatory drugs: report of 2 cases and review. Clin Infect Dis. 2001 Sep 1;33(5):740-4. doi:10.1086/322592 Epub 2001 Aug 6.; Adil M, Amin SS, Arif T. Nicolau's syndrome: A rare but preventable iatrogenic disease. Acta Dermatovenerol Croat. 2017 Oct;25(3):251-3.; Kim SK, Kim TH, Lee KC. Nicolau syndrome after intramuscular injection: 3 cases. Arch Plast Surg. 2012 May;39(3):249-52. doi:10.5999/aps.2012.39.3.249. Epub 2012 May 10.; Luton K, Garcia C, Poletti E, Koester G. Nicolau Syndrome: three cases and review. Int J Dermatol. 2006 Nov;45(11):1326-8. doi:10.1111/j.1365-4632.2006.02674.x; Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi:10.1016/j.ejpain.2006.02.013. Epub 2006 May 8.; Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi:10.1136/ard.2003. 020313. Epub 2004 Apr 13.; Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain. 2011 Jan;27(1):1-8. doi:10.1097/AJP.0b013e3181ed0639; DeLemos B, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011 May;18(3):216-26. doi:10.1097/MJT. 0b013e3181cec307; Innes G, Croskerry P, Worthington J, et al. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med. 1998 Jul-Aug;16(4):549-56. doi:10.1016/S0736-4679(98)00044-4; O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, doubleblind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789-802. doi:10.1177/147323000903700615; Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016 Jun;24(6):962-72. doi:10.1016/j.joca. 2016.01.135. Epub 2016 Feb 1.; Кукушкин МЛ. Алгоритмы диагностики и лечения боли в спине. Русский медицинский журнал. 2014;(11):844-8. [Kukushkin ML. Algorithms for diagnosis and treatment of back pain. Russkii Meditsinskii Zhurnal. 2014;(11):844-8 (In Russ.)].; Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2016 Oct 10. pii: S0140-6736(16)30970-9. doi:10.1016/S0140-6736(16)30970-9; Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Feb 14. doi:10.7326/M16-2367; Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi:10.1002/14651858. CD012087; Malanga G, Wolff E. Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics. Spine J. 2008 Jan-Feb;8(1): 173-84. doi:10.1016/j.spinee.2007.10.013; Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi:10.2147/JPR.S6775. Epub 2012 Nov 28.; White AP, Arnold PM, Norvell DC, et al. Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S131-43. doi:10.1097/ BRS.0b013e31822f178f; Barrington JW, Halaszynski TM, Sinatra RS, et al. Perioperative pain management in hip and knee replacement surgery. Am J Orthop (Belle Mead NJ). 2014 Apr;43(4 Suppl):S1-S16.; Elmallah RK, Cherian JJ, Pierce TP, et al. New and Common Perioperative Pain Management Techniques in Total Knee Arthroplasty. J Knee Surg. 2016 Feb;29(2):169-78. doi:10.1055/s0035-1549027. Epub 2015 Apr 18.; Regan DW, Kashiwagi D, Dougan B, et al. Update in perioperative medicine: practice changing evidence published in 2016. Hosp Pract (1995). 2017 Oct;45(4):158-64. doi:10.1080/21548331.2017. 1359060. Epub 2017 Jul 28.; De Oliveira GS Jr, Agarwal D, Benzon HT. Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesth Analg. 2012 Feb;114(2):424-33. doi:10.1213/ANE.0b013e3182334d68. Epub 2011 Sep 29.; Cepeda MS, Carr DB, Miranda N, et al. Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial. Anesthesiology. 2005 Dec;103(6):1225-32. doi:10.1097/00000542-200512000-00018; McDaid C, Maund E, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess. 2010 Mar;14(17):1-153, iii-iv. doi:10.3310/hta14170; Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014 Jun 1;32(16):1677-90. doi:10.1200/JCO.2013. 52.8356. Epub 2014 May 5.; Rodriguez MJ, Contreras D, Galvez R, et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain. 2003 Jul;104(1-2):103-10. doi:10.1016/S0304-3959(02)00470-0; Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002 Jul;38(10):1358-63. doi:10.1016/S0959-8049(02)00102-8; Pannuti F, Robustelli della Cuna G, Ventaffrida V, et al. A doubleblind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori. 1999 Mar-Apr;85(2):96-100.; Liu Z, Xu Y, Liu ZL, et al. Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. Int J Clin Oncol. 2017 Oct;22(5):980-5. doi:10.1007/s10147-017-1133-y. Epub 2017 May 8.; Gaertner J, Stamer UM, Remi C, et al. Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med. 2017 Jan;31(1):26-34. doi:10.1177/0269216316655746. Epub 2016 Jul 20.; McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD005180. doi:10.1002/14651858. CD005180; Derry S, Wiffen PJ, Moore RA, et al. Oral nonsteroidal antiinflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017 Jul 12;7:CD012638. doi:10.1002/14651858.CD012638.pub2; Reid J, Hughes CM, Murray LJ, et al. Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med. 2013 Apr;27(4): 295-303. doi:10.1177/ 0269216312441382. Epub 2012 Mar 26.; Luyten FP, Geusens P, Malaise M, et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2007 Jan;66(1):99-106. doi:10.1136/ard. 2006.052308. Epub 2006 Jun 30.; Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi:10.3899/jrheum.110636. Epub 2011 Nov 1.; Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl): S3-11. doi:10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.; Qaseem A, Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. doi:10.7326/M16-0570. Epub 2016 Nov 1.; Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi:10.1136/annrheumdis2016-209707. Epub 2016 Jul 25.; Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi:10.1002/ 14651858.CD010120.pub2; Schumacher H, Boice J, Dahikh D, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-92. doi:10.1136/bmj.324.7352. 1488; Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi:10.1007/s10067-015-2991-1. Epub 2015 Jun 24.; Becker MA, Fitz-Patrick D, Choi HK, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi:10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.; Blachier M, Canoui-Poitrine F, Dougados M, et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013 Sep; 52(9):1686-93. doi:10.1093/rheumatology/ket207. Epub 2013 Jun 13.; Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi:10.1016/j.rdc. 2012.08.005. Epub 2012 Sep 15.; Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi:10.1002/14651858.CD010952.pub2; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978-91. doi:10.1136/ annrheumdis-2016-210770. Epub 2017 Jan 13.; Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. doi:10.1002/art.21054; Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S18-21. doi:10.1016/j.semarthrit.2015.11.007. Epub 2015 Dec 2.; Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs. 2011 Jul 9;71(10):1259-79. doi:10.2165/11592550-000000000-00000; Kneer W, Rother I, Rother M, et al. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf. 2009 Jan;4(1):5-10. doi:10.2174/157488609787354468; Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100 mg) for the treatment of ankle sprain: a randomized, doubleblind, placebo-controlled study. Am J Sports Med. 2005 Apr; 33(4):515-23. doi:10.1177/0363546504268135 Epub 2005 Feb 8.; Baraf HS, Gloth FM, Barthel HR, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, doubleblind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging. 2011 Jan 1;28(1):27-40. doi:10.2165/11584880-000000000-00000; Derry S, Moore RA, Gaskell H, et al. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015 Jun 11;(6):CD007402. doi:10.1002/14651858.CD007402.pub3; Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi:10.2147/JPR.S75160. eCollection 2015.; Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal AntiInflammatory Drugs. Gastroenterology. 2018 Feb;154(3):500-14. doi:10.1053/j.gastro.2017.10.049. Epub 2017 Dec 6.; Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3. doi:10.1186/ar4175. Epub 2013 Jul 24.; Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-8. doi:10.1159/ 000452356. Epub 2017 Jan 5.; Lain L. Proton pump inhibitor co-therapy with nonsteroidal antiinflammatory drugs – nice or necessary? Rev Gastroenterol Disord. 2004;4 Suppl 4:S33-41.; Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004 Aug;50(8):2433-40. doi:10.1002/art.20440; Brooks J, Warburton R, Beales IL. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis. 2013 Sep;4(5):206-22. doi:10.1177/ 2040622313492188; Scheiman J. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians. J Clin Gastroenterol. 2016 Jan;50(1):5-10. doi:10.1097/MCG.0000000000000432; Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007 Sep;5(9): 1040-5. doi:10.1016/j.cgh.2007.04.031 Epub 2007 Jul 10.; Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J. 2006 Mar;82(965):186-91. doi:10.1136/ pgmj.2005.039586; Taki M, Oshima T, Tozawa K, et al. Analysis of risk factors for colonic diverticular bleeding and recurrence. Medicine (Baltimore). 2017 Sep;96(38):e8090. doi:10.1097/MD.0000000000008090; Nagata N, Niikura R, Yamada A, et al. Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study. PLoS One. 2016 Mar 15;11(3):e0151332. doi:10.1371/ journal.pone.0151332. eCollection 2016.; Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22. doi:10.1111/j.1365-2036.2007.03312.x; Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol. 2008 May;6(5):536-44. doi:10.1016/j.cgh. 2007.12.023. Epub 2008 Jan 31.; Stein J, Connor S, Virgin G, et al. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016 Sep 21;22(35):7908-25. doi:10.3748/wjg.v22.i35.7908; Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. Open Rheumatol J. 2012;6:44-9. doi:10.2174/1874312901206010044. Epub 2012 May 11.; Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi:10.1185/03007995.2011. 581274. Epub 2011 May 12.; Lanas A. A review of the gastrointestinal safety data – a gastroenterologist's perspective. Rheumatology (Oxford). 2010 May;49 Suppl 2:ii3-10. doi:10.1093/rheumatology/keq058; Каратеев АЕ, Насонов ЕЛ. Неязвенная диспепсия, ассоциированная с приемом НПВП: возможность применения антацидных препаратов. Научно-практическая ревматология. 2003;41(2):28-30 [Karateev AE, Nassonov EL. Non-ulcer dyspepsia associated with NSAID intake: possibility of antacid drugs application. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(2):28-30 (In Russ.)]. doi:10.14412/1995-4484-2003-765; Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202. doi:10.1016/ S1542-3565(05)00980-8; Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009 Oct;65(10):963-70. doi:10.1007/s00228-009-0719-3. Epub 2009 Aug 27.; Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015 Mar;50(3):255-63. doi:10.3109/ 00365521.2014.966753. Epub 2014 Oct 14.; Hensley A, Beales IL. Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals (Basel). 2015 Sep 7;8(3): 512-24. doi:10.3390/ph8030512; Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9 [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya 2003;12(1):64-9 (In Russ.)].; Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2018 Feb 21. doi:10.1111/bph.14167 [Epub ahead of print].; Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006 Mar;1(2):236-45. doi:10.2215/CJN. 00890805. Epub 2006 Feb 1.; Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004 Mar;43(3):525-30. doi:10.1161/01. HYP.0000116221.27079.ea Epub 2004 Jan 19.; Singh G, Miller JD, Lee FH, et al. Pevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination survey. Am J Manag Care. 2002;8(Suppl 15):83-91.; Harley C, Wagner S. The prevalence of cardiovascular risk factors in parients prescribing anti-inflammatory drugs; data from managed care. Clin Ther. 2003;25:139-49. doi:10.1016/S0149-2918(03)90017-8; Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgestic use and risk of hypertension in younger woman. Arch Intern Med. 2002;162:2204-8. doi:10.1001/archinte.162.19.2204; Formam J, Stampfer M, Curhan G. Non-narcotic analgetic dose and risk of incident hypertension in US women. Hypertension. 2005 Sep;46(3):500-7. doi:10.1161/01.HYP.0000177437. 07240.70. Epub 2005 Aug 15.; Solomon D, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-5. doi:10.1161/01.HYP.0000136134. 31846.83; Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;284:1247-55. doi:10.1001/jama.284.10.1247; Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006;119:255-66. doi:10.1016/j.amjmed.2005.09.054; Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-81. doi:10.1016/S0140-6736(06)69666-9; Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi:10.1056/NEJMoa1611593. Epub 2016 Nov 13.; Aw T, Haas S, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-6. doi:10.1001/archinte.165.5.ioi50013; Chan C, Reid C, Aw T, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332-41. doi:10.1097/HJH.0b013e3283310dc9; Watkins J, Abbott E, Hensby C, et al. Attenuation of hypotensive effect of propranalol and thiaside diuretics by indomethacin. Br Med J. 1980;281:702-5. doi:10.1136/bmj.281.6242.702; Polonia J, Boaventure J, Gama G, et al. Influence of nonsteroidal antiinflammatory drugs on renal function and 24-hour blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995;13:925-31. doi:10.1097/00004872-199508000-00014; Wong D, Spence J, Lamki L, et al. Effect of nonsteroidal antiinflammatory drugs on control of hypertension of beta-blockers and diuretics. Lancet. 1986;1:997-1001. doi:10.1016/S0140-6736 (86)91271-7; Baez M, Alvarez C, Weilder D. Effects of the non-steroidal antiinflammatory drugs, piroxicam or sulindac, on the antihypertensive action of propranolol and verapamil. J Hypertension. 1987; Suppl. 5:563-6.; Cinquegrani M, Liang C. Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment. Clin Exp Hypertension. 1988;10:411-31. doi:10.3109/10641968809033901; Hardy B, Bartle W, Myers M, et al. Effects of indomethacin on the pharmakokinetics of felodipine. Br J Clin Pharmacol. 1988;26:557-67. doi:10.1111/j.1365-2125.1988.tb05295.x; Houston M, Weir M, Gray J, et al. The effects of non-steroidal antiinflammatory drugs on blood pressure of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155: 1049-54. doi:10.1001/archinte.1995.00430100075009; Klassen D, Goadfriend T, Schuma A, et al. Assesment of Blood pressure during treatment with naproxen of ibuprofen in hypertensive patients treated with hydrochlorthiazide. J Clin Pharmacol. 1993;33(10): 971-8. doi:10.1002/j.1552-4604.1993.tb01932.x; Johnson D, Hisel T, Phillips B. Effect of cyclooxygenase-2 inhibitors on blood pressure. Ann Pharmacother. 2003;37:442-6. doi:10.1345/aph.1C277; Whelton A, Fort J, Puma J, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95. doi:10.1097/00045391-200103000-00003; Whelton A, White W, Bello A, et al. SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systolic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63. doi:10.1016/S0002-9149(02)02661-9; Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42:985-94. doi:10.1177/0091270002042009005; Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008 Fall;15(3): e372-82. Epub 2008 Oct 24.; Aljadhey H, Tu W, Hansen RA, et al. Comparative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012 Oct 24;12:93. doi:10.1186/1471-2261-12-93; Villa J, Cano A, Franco D, et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria. 2014 Nov;46(9):464-74 (In Span.). doi:10.1016/j.aprim.2013.11.010. Epub 2014 Mar 22.; Elliott WJ. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Curr Hypertens Rep. 2010 Aug;12(4):258-66. doi:10.1007/ s11906-010-0120-8; White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007 Jan 1;99(1):91-8. doi:10.1016/ j.amjcard.2006.07.069. Epub 2006 Nov 10.; Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539-41. doi:10.1126/science.1068711; Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenes an opportunities. J Clin Invest. 2006 Jan;116(1):4-15. doi:10.1172/JCI27291; Schaeverbeke T, Heloire F, Deray G. How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006 Sep;35 Suppl 1:41-6. doi:10.1016/S0755-4982(06)74939-9; Laine L, White WB, Rostom A, Hochberg M. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Semin Arthritis Rheum. 2008 Dec;38(3):165-87. doi:10.1016/j.semarthrit.2007. 10.004. Epub 2008 Jan 4.; Vonkeman HE, Brouwers JR, van de Laar MA. Understanding the NSAID related risk of vascular events. BMJ. 2006 Apr 15;332(7546):895-8. doi:10.1136/bmj.332.7546.895; Fosbol EL, Kober L, Torp-Pedersen C, Gislason GH. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf. 2010 Nov;9(6):893-903. doi:10.1517/14740338.2010.501331; Boulakh L, Gislason GH. Treatment with non-steroidal antiinflammatory drugs in patients after myocardial infarction – a systematic review. Expert Opin Pharmacother. 2016 Jul;17(10): 1387-94. doi:10.1080/14656566.2016.1186648. Epub 2016 May 23.; Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27;113(25): 2906-13. doi:10.1161/CIRCULATIONAHA.106.616219. Epub 2006 Jun 19.; Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015 Feb 24;313(8):805-14. doi:10.1001/jama.2015.0809; Richman IB, Owens DK. Aspirin for Primary Prevention. Med Clin North Am. 2017 Jul;101(4):713-24. doi:10.1016/j.mcna.2017. 03.004; Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809-17. doi:10.1056/NEJMoa003199; Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005 Apr 19;45(8):1295-301. doi:10.1016/j.jacc. 2005.01.045; Van Solingen RM, Rosenstein ED, Mihailescu G, et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med. 2001 Sep;111(4):285-9. doi:10.1016/S0002-9343(01)00838-5; Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthe volunteers. J Clin Pharmacol. 2002 Sep;42(9):1027-30. doi:10.1177/ 0091270002042009010; Van Ryn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004 Jul;44(7):777-84. doi:10.1177/0091270004266623; MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-4. doi:10.1016/S0140-6736(03)12509-3; Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, GonzalezPerez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004 Jun 22;109(24):3000-6. doi:10.1161/01.CIR.0000132491.96623. 04. Epub 2004 Jun 14.; Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefit of aspirin on first myocardial infarction by non-steroidal antiinflammatory drugs. Circulation. 2003 Sep 9;108(10):1191-5. doi:10.1161/01.CIR.0000087593.07533.9B Epub 2003 Aug 25.; Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol. 2005 Aug;32(8):1589-93.; Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction. BMJ. 2003 Dec 6;327(7427): 1322-3. doi:10.1136/bmj.327.7427.1322; Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med. 2004 Apr 26;164(8):852-6. doi:10.1001/archinte.164.8.852; Singh G, Graham D, Wang H, et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65 Suppl. II:61 (OP0024 abst).; Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Antiinflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Clin Cardiol. 2016 Feb;39(2):111-8. doi:10.1002/clc.22502. Epub 2015 Dec 31.; Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008 Nov; 10(11):1102-7. doi:10.1016/j.ejheart.2008.07.013. Epub 2008 Aug 29.; Girouard C, Gregoire JP, Poirier P, Moisan J. Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore). 2017 Mar;96(9):e6239. doi:10.1097/MD. 0000000000006239; Hudson M, Richard H, Pilote L. Different in outcome of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005 Jun 11;330(7504):1370. doi:10.1136/bmj.330.7504.1370; Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005 May;44(5):677-80. doi:10.1093/rheumatology/keh610. Epub 2005 Mar 22.; Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in eldery patients: a population-based cohort study. Lancet. 2004 May 29;363(9423):1751-6. doi:10.1016/S0140-6736(04)16299-5; Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi:10.1136/bmj.i4857; Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003 Mar;14(2):240-6. doi:10.1097/01.EDE. 0000034633.74133.C3; Bä ck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012 Aug;33(15):1928-33. doi:10.1093/eurheartj/ehr421. Epub 2011 Nov 21.; Liu G, Yan YP, Zheng X, et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol. 2014 Nov 15;114(10):1523-9. doi:10.1016/j.amjcard.2014.08.015. Epub 2014 Aug 27.; Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011 Jul 4;343:d3450. doi:10.1136/bmj.d3450; Chuang SY, Hsu PF, Lin F, et al. Association between Nonsteroidal Anti-inflammatory Drugs and Atrial Fibrillation among a Middle-aged Population: A Nationwide Populationbased Cohort. Br J Clin Pharmacol. 2018 Mar 20. doi:10.1111/ bcp.13558 [Epub ahead of print].; Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009 Nov;8(6):669-81. doi:10.1517/14740330903311023; Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal antiinflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi:10.1186/s12882-017-0673-8; Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi:10.1053/j.ajkd.2004.12.005; Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 2013 Nov;62(5):1012-7. doi:10.1053/j.ajkd.2013.03.045. Epub 2013 Jun 14.; Lipworth L, Abdel-Kader K, Morse J, et al. High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. BMC Nephrol. 2016 Nov 24;17(1):189. doi:10.1186/s12882-016-0411-7; Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi:10.1161/ HYPERTENSIONAHA.114.05105. Epub 2015 Jul 13.; Mö ller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2013 Dec 19. doi:10.1136/ annrheumdis-2013-204078 [Epub ahead of print].; Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013 Jun;30(3):247-55. doi:10.1093/fampra/ cms086. Epub 2013 Jan 8.; Souter A. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg. 1994 Dec;79(6):1178-90. doi:10.1213/00000539-199412000-00025; Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and the risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82. doi:10.1001/jama.1996.03530290046036; Weber EW, Slappendel R, Durieux ME, et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003 Dec;20(12):963-6. doi:10.1097/00003643-200312000-00005; Bricker SR, Savage ME, Hanning CD. Perioperative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987 Nov;4(6):429-34.; Wierod FS, Frandsen NJ, Jacobsen JD, et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998 Apr;32(2): 120-2. doi:10.1080/003655998750014495; Nikanne E, Kokki H, Salo J, Linna TJ. Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg. 2005 Feb;132(2):287-94. doi:10.1016/j.otohns.2004.09.005; Moiniche S, Romsing J, Dahl JB, Tramrr MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: A quantitative systematic review. Anesth Analg. 2003 Jan;96(1):68-77. doi:10.1213/00000539-200301000-00015; Forrest JB, Camu F, Greer IA, et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain re-lief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33. doi:10.1093/bja/88.2.227; Deutsch D, Boustiere C, Ferrari E, et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol. 2017 Jun;10(6):495-505. doi:10.1177/1756283X17702092. Epub 2017 Apr 17.; Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-63. doi:10.3748/ wjg.v23.i11.1954; Мороз ЕВ, Каратеев АЕ, Крюков ЕВ, Чернецов ВА. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675-84 [Moroz EV, Karateev AE, Kryukov EV, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675-684 (In Russ.)]. doi:10.14412/1995-4484-2017-675-684; Elia N, Lysakowski C, Tramer MR. Does Multimodal Analgesia with Acetaminophen, Non-steroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone?: Meta-analyses of Randomized Trials. Anesthesiology. 2005 Dec;103(6):1296-304. doi:10.1097/00000542-200512000-00025; Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis. 2013 Nov;17(4):643-56, ix. doi:10.1016/j.cld.2013.07.009. Epub 2013 Sep 4.; Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010 Dec 7;16(45):5651-61. doi:10.3748/wjg.v16.i45.5651; Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb;104(2):356-62. doi:10.1038/ajg.2008.149. Epub 2009 Jan 27.; Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. doi:10.1016/j.clinthera.2006.08.014; Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003 Jul 5;327(7405):18-22. doi:10.1136/bmj.327.7405.18; Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi:10.1111/bcp.12938. Epub 2016 Apr 27.; Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb;36(2):135-44. doi:10.1007/s40264-012-0013-7; Каратеев АЕ. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium medicum. 2011; 13(9):89-95 [Karateev AE. Russian experience of nimesulide: review of clinical trials. Consilium medicum. 2011;13(9): 89-95 (In Russ.)].; Каратеев АЕ, Журавлева МВ. Анализ спонтанных сообщений российских врачей о неблагоприятных реакциях, возникших на фоне приема нимесулида: гепатотоксические осложнения очень редки. Эффективная фармакотерапия. 2015;(8):4-12 [Karateev AE, Zhuravleva MV. Analysis of spontaneous Russian doctors about the adverse reactions that occurred in patients receiving nimesulide: hepatotoxic complications are very rare. Effektivnaya Farmakoterapiya. 2015;(8):4-12 (In Russ.)].; Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008 Jan;15(1):15-21. doi:10.1097/MOH.0b013e3282f15fb9; Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J. 2005 Sep 1;123(5):247-9. doi:10.1590/S1516-31802005000500009 Epub 2005 Dec 8.; Mourad AA, Bahna S. Hypersensitivities to non-steroidal antiinflammatory drugs. Expert Rev Clin Immunol. 2014 Sep;10(9): 1263-8. doi:10.1586/1744666X.2014.946905. Epub 2014 Aug 4.; Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32. doi:10.1111/all.12260. Epub 2013 Oct 5.; White AA, Stevenson DD. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588-94. doi:10.1055/s-0032-1325618. Epub 2012 Oct 9.; Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. doi:10.1007/s11882-004-0037-x; Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2. doi:10.1186/ar4174. Epub 2013 Jul 24.; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.; Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):81-5. doi:10.3760/cma.j.issn.0578-1426.2017.01.021; Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi:10.1136/ard.2010. 128660. Epub 2010 Sep 10.; Singh G, Triadafilopoulos S. Appropriative choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract. 2005 Oct;59(10):1210-7. doi:10.1111/j.1368-5031.2005.00660.x; Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8): 1453-8. doi:10.1136/ard.2009.123166. Epub 2010 May 24.; Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report Gut. 2017 Jan;66(1):6-30. doi:10.1136/gutjnl2016-312288. Epub 2016 Oct 5.; Huang J, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22. doi:10.1016/ S0140-6736(02)07273-2; Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol. 2015 May;110(5):684-9. doi:10.1038/ajg.2015.98. Epub 2015 Apr 21.; Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003. doi:10.1016/S0195-668X(03)00114-3; Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96. doi:10.1177/2047487316653709. Epub 2016 Jun 27.; Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi:10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.; Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi:10.1186/ar4134; Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17; 376(9736):173-9. doi:10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.; Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-82. doi:10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi:10.2165/ 11633470-000000000-00000; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/ journal.pone.0190798. eCollection 2018.; Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. doi:10.1016/S0140-6736(07)60234-7; Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov;135(5):1517-25. doi:10.1053/j.gastro.2008.07.067. Epub 2008 Aug 3.; Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107:48-54. doi:10.1016/S0002-9343(99) 00367-8; Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi:10.1097/MD. 0000000000001592; Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med. 2004 Jul 15;117(2):100-6. doi:10.1016/j.amjmed.2004.03.012; Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):365-75. doi:10.1002/pds.3385; Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi:10.2165/00003495-200161090-00012; Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94 [Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94 (In Russ.)]. doi:10.14412/1996-7012-2017-4-89-94; Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan; 130(1):55-71. doi:10.1080/00325481.2018.1412799. Epub 2017 Dec 15.; Tacconelli S, Bruno A, Grande R, et al. Nonsteroidal antiinflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. Expert Opin Drug Saf. 2017 Jul;16(7):791-807. doi:10.1080/14740338.2017.1338272. Epub 2017 Jun 8.; Antman EM. Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. Circulation. 2017 May 23;135(21):2062-72. doi:10.1161/CIRCULATIONAHA.117. 027288; Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi:10.1136/bmj.c7086; Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Safety. 2013;22:559-70. doi.org/10.1002/pds.3437; Eisner F, Hermann D, Bajaeifer K, et al. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience. Visc Med. 2017 Jun;33(3):221-6. doi:10.1159/000475450. Epub 2017 Jun 16.; Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15. doi:10.1053/j.gastro.2017.01.031; Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi:10.5009/gnl15502; Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179. doi:10.1186/s12916-016-0718-z; Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol. 2014 Dec; 12(4):398-413. doi:10.1007/s11938-014-0029-4; Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi:10.1186/ar4177. Epub 2013 Jul 24.; Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jun;33(6):973-80. doi:10.1080/03007995.2017.1281110. Epub 2017 Jan 25.; Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May;119(5):448.e27-36. doi:10.1016/j.amjmed.2005.11.020; Каратеев АЕ. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013;51(3):332-40 [Karateev AE. Six stabs in the back of proton pump inhibitors. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):332-40 (In Russ.)]. doi:10.14412/1995-4484-2013-1509; Maes ML, Fixen DR, Linnebur SA. Adverse effects of protonpump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017 Sep;8(9):273-97. doi:10.1177/20420986 17715381. Epub 2017 Jun 29.; Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi:10.1038/ nrgastro.2017.117. Epub 2017 Sep 20.; Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr; 37(4):201-11. doi:10.1007/s40264-014-0144-0; Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. doi:10.1038/clpt.2010.219; Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi:10.1124/dmd.112.045575. Epub 2012 May 30.; Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 Jul;42(7):633-40. doi:10.3109/ 00498254.2011.653655. Epub 2012 Feb 7.; Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7. doi:10.1097/FJC.0b013e3181e19739; Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9): 937-44. doi:10.1001/jama.2009.261; Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-8. doi:10.1503/cmaj.082001; Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014 May;126(3):239-45. doi:10.3810/pgm.2014. 05.2772; Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol. 2006 Apr;101(4):701-10. doi:10.1111/j.1572-0241.2006.00499.x Epub 2006 Feb 22.; Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi:10.1016/S0140-6736(07)60749-1; Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012;17:286-96. doi:10.1111/j.1523-5378.2012.00942.x; Ивашкин ВТ, Маев ИВ, Лапина ТЛ и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):4-21 [Ivashkin VT, Maev IV, Lapina TL, et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and the resolution of the Expert Council of the Russian Gastroenterological Association on May 19, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):4-21 (In Russ.)].; Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018 May;34(3):175-82. doi:10.1097/MOG. 0000000000000427; Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory DrugInduced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016 Jun;14(6):809-15.e1. doi:10.1016/j.cgh.2015.10.022. Epub 2015 Oct 30.; Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015 Apr; 50(4):387-93. doi:10.1007/s00535-014-1032-1. Epub 2015 Jan 10.; Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol. 2009;54:309-17. doi:10.4166/kjg.2009.54.5.309; Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500-7. doi:10.1007/s10620-008-0507-4; Мороз ЕВ, Каратеев АЕ. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология. 2016;10(4):97-105 [Moroz EV, Karateev AE. Rebamipide: Effective drug prevention of NSAID enteropathy is possible. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):97-105 (In Russ.)]. doi:10.14412/1996-7012-2016-4-97-105; Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Dec 1. doi:10.1007/s10620-017-4871-9 [Epub ahead of print].; Hasegawa M, Horiki N, Tanaka K, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013 Nov;23(6):1172-8. doi:10.1007/s10165-012-0819-2. Epub 2013 Jan 10.; Park SH, Cho CS, Lee OY, et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled TrialSTORM STUDY. J Clin Biochem Nutr. 2007 Mar;40(2):148-55. doi:10.3164/jcbn.40.148; Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014 Jul;8(4):371-9. doi:10.5009/gnl. 2014.8.4.371. Epub 2013 Dec 24.; Kurokawa S, Katsuki S, Fujita T, et al. A randomized, doubleblinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014 Feb;49(2):239-44. doi:10.1007/s00535-013-0805-2. Epub 2013 Apr 18.; Watanabe T, Takeuchi T, Handa O, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-tosevere small intestinal damage. PLoS One. 2015 Apr 15;10(4): e0122330. doi:10.1371/journal.pone.0122330. eCollection 2015.; Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi:10.1007/s10620-013-2606-0. Epub 2013 Feb 28.; Yokoyama H, Ito N, Soeda S, et al. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther. 2013 Feb;38(1):12-5. doi:10.1111/j.1365-2710.2012. 01373.x. Epub 2012 Aug 6.; Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013 May;109(5):825-33. doi:10.1160/TH12-07-0532. Epub 2012 Dec 13.; Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013 Mar;69(3):365-71. doi:10.1007/s00228-012-1370-y. Epub 2012 Aug 14.; Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007 Dec 22;370(9605):2138-51. doi:10.1016/S0140-6736(07)61909-6; Группа экспертов под председательством С.А. Бойцова и Н.В. Погосова. Российское кардиологическое общество. Национальное общество профилактической кардиологии. Российское общество профилактики неинфекционных заболеваний. Кардиоваскулярная профилактика 2017. Доступно по ссылке: http://ropniz.ru/wp-content/uploads/2017/11/CVP_2017. pdf [A panel of experts chaired by S.A. Boytsov and N.V. Pogosov. Russian Cardiology Society. National Society of Preventive Cardiology. Russian Society for the Prevention of Noncommunicable Diseases. Cardiovascular prevention 2017. Available from: http://ropniz.ru/wp-content/uploads/2017/ 11/CVP_2017.pdf].; Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018 Mar 6;168(5):351-8. doi:10.7326/M17-3203. Epub 2018 Jan 23.; Рабочая группа членов Правления Научного общества нефрологов России под руководством А.В. Смирнова. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Санкт-Петербург: Левша; 2012. 51 с. [Working group of members of the Board of the Scientific Society of Nephrologists of Russia under the guidance of A.V. Smirnova. National recommendations. Chronic kidney disease: the basic principles of screening, diagnosis, prevention, and approaches to treatment. St. Petersburg: Levsha; 2012. 51 p.]. ISBN 978-5-93356-129-3; Рабочая группа под руководством Денисова И.Н. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации» Хроническая болезнь почек. Клинические рекомендации. Москва; 2014. Доступно по ссылке: http://sevgb6.ru/doc/ klinicheskie-rekomendacii/hbp.pdf [The working group, led by Denisov I.N. All-Russian Public Organization «Association of General Practitioners (Family Physicians) of the Russian Federation» Chronic kidney disease. Clinical recommendations. Moscow; 2014. Available from: http://sevgb6.ru/doc/klinicheskierekomendacii/hbp.pdf].; Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4; 158(11):825-30. doi:10.7326/0003-4819-158-11-201306040-00007; National Institute for Health and Care Excelence (NICE): Chronic kidney disease in adults: assessment and management. Available at: https://www.nice.org.uk/guidance/cg182 Accessed September 26th 2017.; https://rsp.mediar-press.net/rsp/article/view/2536

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2536
https://doi.org/10.14412/1995-4484-2018-1-29

المؤلفون: E. Nasonov L., N. Yakhno N., A. Karateev E., L. Alekseeva I., A. Barinov N., A. Barulin E., O. Davydov S., A. Danilov B., M. Zhuravleva V., B. Zavodovsky V., S. Kopenkin S., M. Kukishkin L., V. Parfenov A., M. Strakhov A., V. Tyurin P., N. Chichasova V., S. Chorbinskaya A., Е. Насонов Л., Н. Яхно Н., А. Каратеев Е., Л. Алексеева И., А. Баринов Н., А. Барулин Е., О. Давыдов С., А. Данилов Б., М. Журавлева В., Б. Заводовский В., С. Копенкин С., М. Кукушкин Л., В. Парфенов А., М. Страхов А., В. Тюрин П., Н. Чичасова В., С. Чорбинская А.

المصدر: Rheumatology Science and Practice; Vol 54, No 3 (2016); 247-265 ; Научно-практическая ревматология; Vol 54, No 3 (2016); 247-265 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20163

مصطلحات موضوعية: musculoskeletal pain, osteoarthritis, nonspecific back pain, analgesic therapy, interdisciplinary consensus, скелетно-мышечная боль, остеоартроз, неспецифическая боль в спине, анальгетическая терапия, междисциплинарный консенсус

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2206/1423; Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol’ (prakticheskoe rukovodstvo dlya vrachei) [Pain (a practical guide for doctors)]. Moscow: Publishing of Russian Academy of Medical Sciences; 2012. 512 p.].; Яхно НН, Кукушкин МЛ. Хроническая боль: медико-биологические и социально-экономические аспекты. Вестник РАМН. 2012;(9):54-8 [Yakhno NN, Kukushkin ML. Chronic pain: medical-biological and socio-economic aspects. Vestnik RAMN. 2012;(9):54-8 (In Russ.)].; Яхно НН, Баринов АН, Подчуфарова ЕВ. Невропатическая и скелетно-мышечная боль. Современные подходы к диагностике и лечению. Клиническая медицина. 2008;(11):9-15 [Yakhno NN, Barinov AN, Podchufarova EV. Neuropathic and musculoskeletal pain. Current approaches to diagnosis and treatment. Klinicheskaya Meditsina. 2008;(11):9-15 (In Russ.)].; Насонов ЕЛ, Насонова ВА. Фармакотерапия боли: взгляд ревматолога. Consilium medicum. 2000;2(12):7-14 [Nasonov EL, Nasonova VA. Pharmacotherapy of pain: a view of the rheumatologist. Consilium medicum. 2000; 2 (12): 7-14 (In Russ.)].; Кукушкин МЛ, Хитров НК. Общая патология боли. Москва: Медицина; 2004. 144 с. [Kukushkin ML, Khitrov NK. Obshchaya patologiya boli [General pathology of pain]. Moscow: Medicine; 2004. 144 p.].; Голубев ВЛ. Боль – междисциплинарная проблема. Русский медицинский журнал. 2008;16 (Спец. выпуск):3-7 [Golubev VL. The pain – an interdisciplinary problem. Russkii Meditsinskii Zhurnal. 2008;16 (Special Issue):3-7 (In Russ.)].; Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi:10.1016/S0140-6736(12)61729-2; Harker J, Reid K, Bekkering G, et al. Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat. 2012;2012:371248. doi:10.1155/2012/371248; Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull WHO. 2003;81:646-56.; Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333. doi:10.1016/j.ejpain.2005.06.009; Эрдес ШФ, Дубинина ТВ, Галушко ЕА. Боли в нижней части спины в общеклинической практике. Терапевтический архив. 2008;80(5):59-61 [Erdes ShF, Dubinina TV, Galushko EA. Pain in the lower back in the general clinical practice. Terapevticheskii Arkhiv. 2008;80(5):59-61 (In Russ.)].; Friedly J, Standaert C, Chan L. Epidemiology of spine care: the back pain dilemma. Phys Med Rehabil Clin N Am. 2010;21(4):659-77. doi:10.1016/j.pmr.2010.08.002; Juniper M, Le T, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother. 2009;10(16):2581-92. doi:10.1517/14656560903304063; Litwic A, Edwards M, Dennison E, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99. doi:10.1093/bmb/lds038; Zhang Y, Jordan J. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355-69. doi:10.1016/j.cger.2010.03.001; Murphy L, Helmick C. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012;112(3 Suppl 1):13-9. doi:10.1097/01.NAJ.0000412646.80054.21; Millar NL, Murrell GA, McInnes IB. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology (Oxford). 2013 May;52(5):769-79. doi:10.1093/rheumatology/kes409. Epub 2013 Jan 28.; Scott A, Ashe MC. Common tendinopathies in the upper and lower extremities. Curr Sports Med Rep. 2006 Sep;5(5):233-41. doi:10.1097/01.CSMR.0000306421.85919.9c; Van Tulder M, Malmivaara A, Koes B. Repetitive strain injury. Lancet. 2007;369(9575):1815-22. doi:10.1016/S0140-6736(07)60820-4; Кукушкин МЛ, Табеева ГР, Подчуфарова ЕВ. Болевой синдром: патофизиология, клиника, лечение. Москва: ИМА-ПРЕСС; 2011. 72 с. [Kukushkin ML, Tabeeva GR, Podchufarova EV. Bolevoi sindrom: patofiziologiya, klinika, lechenie [Pain syndrome: pathophysiology, clinical features, treatment]. Moscow: IMA-PRESS; 2011. 72 p.].; Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011 Dec;13(6):513-20. doi:10.1007/s11926-011-0206-6; Edmonds S. Therapeutic targets for osteoarthritis. Maturitas. 2009 Jul 20;63(3):191-4. doi:10.1016/j.maturitas.2009.03.015. Epub 2009 May 6.; Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol. 2005 Sep;17(5):624-8. doi:10.1097/01.bor.0000172800.49120.97; Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013 Jun 1;87(11):766-72.; Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009 May-Jun;31(3):206-19. doi:10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.; Насонова ВА, Фоломеева ОМ, Эрдес ШФ. Ревматические заболевания в Российской Федерации в начале XXI века глазами статистики. Терапевтический архив. 2009;(6):5-10 [Nasonova VA, Folomeeva OM, Erdes ShF. Rheumatic diseases in the Russian Federation at the beginning of the XXI century through the eyes of statistics. Terapevticheskii Arkhiv. 2009;(6):5-10 (In Russ.)].; Балабанова РМ, Эрдес ШФ. Распространенность ревматических заболеваний в России в 2012-2013 гг. Научно-практическая ревматология. 2015;52(2):120-4 [Balabanova RM, Erdes ShF. The incidence and prevalence of rheumatic diseases in Russia in 2012–2013. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):120-4 (In Russ.)]. doi:10.14412/1995-4484-2015-120-124; Каратеев АЕ. Болезни костно-мышечной системы в практике 2102 врачей разных специальностей: структура патологии и мнение специалистов об эффективности НПВП (предварительные данные эпидемиологического исследования КОРОНА-2). Consilium medicum, 2013;15(9):95-100 [Karateev AE. Diseases of the musculoskeletal system in practice in 2102 doctors of different specialties: pathology structure and experts' opinion on the effectiveness of non-steroidal anti-inflammatory drugs (preliminary data of CROWN-2 epidemiological studies). Consilium medicum. 2013;15(9):95-100. (In Russ.)].; McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi:10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.; Bruyere O, Cooper C, Pelletier J-P, et al. An algorithm recommendation for the management of knee Osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253-63. doi:10.1016/j.semarthrit.2014.05.014; Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12):2075-94. doi:10.1007/s00586-010-1502-y; Van Hecke O, Torrance N, Smith B. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013;111(1):13-8. doi:10.1093/bja/aet123; Smith B, Elliott A, Hannaford P, Chambers W. Factors related to the onset and persistence of chronic back pain in the community: results from a general population follow-up study. Spine. 2004;29(9):1032-40. doi:10.1097/00007632-200405010-00016; Bergman S, Herrstrom P, Jacobsson L, Petersson I. Chronic widespread pain: a three year follow-up of pain distribution and risk factors. J Rheumatol. 2002;29:818-25.; Andersen JC. Is immediate imaging important in managing low back pain? J Athl Train. 2011 Jan-Feb;46(1):99-102. doi:10.4085/1062-6050-46.1.99; Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for lowback pain: systematic review and meta-analysis. Lancet. 2009 Feb 7;373(9662):463-72. doi:10.1016/S0140-6736(09)60172-0; Jarvik J, Gold L, Comstock B, et al. Association of early imaging for back pain with clinical outcomes in older adults. JAMA. 2015;313(11):1143-53. doi:10.1001/jama.2015.1871; Igarashi A, Kikuchi S, Konno S, Olmarker K. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders. Spine (Phila Pa 1976). 2004 Oct 1;29(19):2091-5. doi:10.1097/01.brs.0000141265.55411.30; Genevay S, Finckh A, Payer M, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine (Phila Pa 1976). 2008 Sep 1;33(19):2041-6. doi:10.1097/BRS.0b013e318183bb86; Cuellar JM, Golish SR, Reuter MW, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010 Mar;10(3):212-8. doi:10.1016/j.spinee.2009.12.007; Schaible H. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep. 2012;14(6):549-56. doi:10.1007/s11926-012-0279-x; Walsh D, Bonnet C, Turner E, et al. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage. 2007 Jul;15(7):743-51. Epub 2007 Mar 21. doi:10.1016/j.joca.2007.01.020; Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001 Jun;44(6):1237-47. doi:10.1002/1529-0131(200106)44:63.0.CO;2-F; Alvarez-Soria MA, Largo R, Santillana J, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis. 2006 Aug;65(8):998-1005. Epub 2006 Feb 13. doi:10.1136/ard.2005.046920; McCarberg BH, Ruoff GE, Tenzer-Iglesias P, Weil AJ. Diagnosis and treatment of low-back pain because of paraspinous muscle spasm: a physician roundtable. Pain Med. 2011 Nov;12 Suppl 4:S119-27. doi:10.1111/j.1526-4637.2011.01253.x; Lund JP, Donga R, Widmer CG, Stohler CS. The pain-adaptation model: a discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharmacol. 1991;69:683-94. doi:10.1139/y91-102; Roland M. A critical review of the evidence for pain-spasm-pain cycle in spinal disorders. Clin Biomech. 1986;1:102-9. doi:10.1016/0268-0033(86)90085-9; Iglesias-Gonzalez JJ, Munoz-Garcia MT, Rodrigues-de-Souza DP, et al. Myofascial trigger points, pain, disability, and sleep quality in patients with chronic nonspecific low back pain. Pain Med. 2013 Dec;14(12):1964-70. doi:10.1111/pme.12224. Epub 2013 Aug 15.; Ramsook RR, Malanga GA. Myofascial low back pain. Curr Pain Headache Rep. 2012 Oct;16(5):423-32. doi:10.1007/s11916-012-0290-y; Fisher NM, Pendergast DR. Reduced muscle function in patients with osteoarthritis. Scand J Rehabil Med. 1997 Dec;29(4):213-21.; Arokoski MH, Arokoski JP, Haara M, et al. Hip muscle strength and muscle cross sectional area in men with and without hip osteoarthritis. J Rheumatol. 2002 Oct;29(10):2185-95.; Blume C, Wang SS. Comparison of changes in supraspinatus muscle thickness in persons with subacromial impingement syndrome and asymptomatic adults. Physiother Theory Pract. 2014 Nov;30(8):544-51. doi:10.3109/09593985.2014.902522. Epub 2014 Mar 28.; Silldorff MD, Choo AD, Choi AJ, et al. Effect of supraspinatus tendon injury on supraspinatus and infraspinatus muscle passive tension and associated biochemistry. J Bone Joint Surg Am. 2014 Oct 15;96(20):e175. doi:10.2106/JBJS.M.01315; Thomopoulos S, Parks WC, Rifkin DB, Derwin KA. Mechanisms of tendon injury and repair. J Orthop Res. 2015 Jan 29. doi:10.1002/jor.22806 [Epub ahead of print].; Millar NL, Hueber AJ, Reilly JH, et al. Inflammation is present in early human tendinopathy. Am J Sports Med. 2010;38(10):2085-91. doi:10.1177/0363546510372613. Epub 2010 Jul 1.; McGonagle D, Benjamin M. Entheses, entehesitis and enthesopathy. Report of rheumatic diseases, series 6, autumn 2009, №4. Available from: www.arc.org.uk/arthinfo/rdr.asp; Gotoh M, Hamada K, Yamakawa H, et al. Interleukin-1-induced glenohumeral synovitis and shoulder pain in rotator cuff diseases. J Orthop Res. 2002 Nov;20(6):1365-71. doi:10.1016/S0736-0266(02)00063-3; Voloshin I, Gelinas J, Maloney MD, et al. Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy. 2005 Sep;21(9):1076.e1-1076.e9. doi:10.1016/j.arthro.2005.05.017; Benjamin M, McGonagle D. Histopathologic changes at «synovio-entheseal complexes» suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum. 2007;56 (11):3601-9. doi:10.1002/art.23078; Haviv B, Bronak S, Thein R. The complexity of pain around the knee in patients with osteoarthritis. Isr Med Assoc J. 2013 Apr;15(4):178-81.; Felson DT. Osteoarthritis as a disease of mechanics. Osteoarthritis Cartilage. 2013 Jan;21(1):10-5. doi:10.1016/j.joca.2012.09.012. Epub 2012 Oct 4.; Tsao H, Tucker KJ, Coppieters MW, Hodges PW. Experimentally induced low back pain from hypertonic saline injections into lumbar interspinous ligament and erector spinae muscle. Pain. 2010 Jul;150(1):167-72. doi:10.1016/j.pain.2010.04.023. Epub 2010 May 26.; Panjabi MM. A hypothesis of chronic back pain: ligament subfailure injuries lead to muscle control dysfunction. Eur Spine J. 2006 May;15(5):668-76. doi:10.1007/s00586-005-0925-3. Epub 2005 Jul 27.; Longo UG, Berton A, Khan WS, et al. Histopathology of rotator cuff tears. Sports Med Arthrosc. 2011 Sep;19(3):227-36. doi:10.1097/JSA.0b013e318213bccb; Ko JY, Wang FS. Rotator cuff lesions with shoulder stiffness: updated pathomechanisms and management. Chang Gung Med J. 2011 Jul-Aug;34(4):331-40.; Raastad J, Reiman M, Coeytaux R, et al. The association between lumbar spine radiographic features and low back pain: A systematic review and meta-analysis. Semin Arthritis Rheum. 2015 Apr;44(5):571-85. doi:10.1016/j.semarthrit.2014.10.006. Epub 2014 Dec 8.; De Schepper EI, Damen J, van Meurs JB, et al. The association between lumbar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. Spine (Phila Pa 1976). 2010 Mar 1;35(5):531-6. doi:10.1097/BRS.0b013e3181aa5b33; Scheele J, de Schepper EI, van Meurs JB, et al. Association between spinal morning stiffness and lumbar disc degeneration: the Rotterdam Study. Osteoarthritis Cartilage. 2012 Sep;20(9):982-7. doi:10.1016/j.joca.2012.05.011. Epub 2012 Jun 12.; Beresford ZM, Kendall RW, Willick SE. Lumbar facet syndromes. Curr Sports Med Rep. 2010 Jan-Feb;9(1):50-6. doi:10.1249/JSR.0b013e3181caba05; Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591-614. doi:10.1097/00000542-200703000-00024; Туровская ЕФ, Алексеева ЛИ, Филатова ЕГ. Современные представления о патогенетических механизмах боли при остеоартрозе. Научно-практическая ревматология. 2014;52(4):438-44 [Turovskaya EF, Alekseeva LI, Filatova EG. Current ideas about the pathogenetic mechanisms of pain in osteoarthrosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):438-44 (In Russ.)]. doi:10.14412/1995-4484-2014-438-444; Mease P, Hanna S, Frakes E, Altman R. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol. 2011;38(8):1546-51. doi:10.3899/jrheum.100759; Hochman J, French M, Bermingham S, Hawker G. The nerve of osteoarthritis pain. Arthritis Care Res (Hoboken). 2010;62(7):1019-23. doi:10.1002/acr.20142; Fishbain DA, Cole B, Lewis JE, Gao J. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2014 Jan;15(1):4-15. doi:10.1111/pme.12229. Epub 2013 Oct 4.; Coombes BK, Bisset L, Vicenzino B. Thermal hyperalgesia distinguishes those with severe pain and disability in unilateral lateral epicondylalgia. Clin J Pain. 2012;28:595-601. doi:10.1097/AJP.0b013e31823dd333; Данилов АБ, Давыдов ОС. Нейропатическая боль. Москва: Боргес; 2007. С. 11, 37-45 [Danilov AB, Davydov OS. Neiropaticheskaya bol’ [Neuropathic pain]. Moscow: Borges; 2007. P. 11, 37-45].; Englbrecht M, Tarner I, van der Heijde D, et al. Measuring pain and efficacy of pain treatment in inflammatory arthritis: A systematic literature review. J Rheumatol Suppl. 2012;90:3-10. doi:10.3899/jrheum.120335; Whittle S, Colebatch A, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology. 2012;51(8):1416-25. doi:10.1093/rheumatology/kes032; Ostelo R, de Vet H. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005;19(4):593-607. doi:10.1016/j.berh.2005.03.003; Stauffer M, Taylor S, Watson D, et al. Definition of nonresponse to analgesic treatment of arthritic pain: An analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam. 2011;2011:231926. doi:10.4061/2011/231926; Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 2001;45(4):384-91. doi:10.1002/1529-0131(200108)45:43.0.CO;2-0; Cepeda M, Africano J, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003;105(1-2):151-7. doi:10.1016/S0304-3959(03)00176-3; Каратеев АЕ. Факторы, влияющие на эффективность обезболивающей терапии. Эффективная фармакотерапия. Неврология и Психиатрия. 2013;47(5):46-53 [Karateev AE. Factors affecting the effectiveness of pain therapy. Effektivnaya farmakoterapiya. Nevrologiya i Psikhiatriya. 2013;47(5):46-53 (In Russ.)].; Farrar J, Young J, La Moreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-58. doi:10.1016/S0304-3959(01)00349-9; Salaffi F, Stancati A, Silvestri C, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283-91. doi:10.1016/j.ejpain.2003.09.004; Kovacs F, Abraira V, Royuela A, et al. Minimum detectable and minimal clinically important changes for pain in patients with nonspecific neck pain. BMC Musculoskelet Disord. 2008;9:43. doi:10.1186/1471-2474-9-43; Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23. (In Russ.)]. doi:10.14412/1996-7012-2015-1-4-23; Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi:10.2147/JPR.S75160. eCollection 2015.; Daniels S, Bandy D, Christensen S, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain. 2011;27(1):1-8. doi:10.1097/AJP.0b013e3181ed0639; Brattwall M, Turan I, Jakobsson J. Pain management after elective hallux valgus surgery: a prospective randomized double-blind study comparing etoricoxib and tramadol. Anesth Analg. 2010;111(2):544-9. doi:10.1213/ANE.0b013e3181e3d87c; O'Donnell J, Ekman E, Spalding W, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flareup of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009;37(6):1789-802. doi:10.1177/147323000903700615; DeLemos B, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011;18(3):216-26. doi:10.1097/MJT.0b013e3181cec307; Innes G, Croskerry P, Worthington J, et al. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med. 1998 Jul-A Aug;16(4):549-56. doi:10.1016/S0736-4679(98)00044-4; Beaulieu A, Peloso P, Haraoui B, et al. Once-daily, controlledrelease tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag. 2008;13(2):103-10. doi:10.1155/2008/903784; Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. Epub 2006 May 8. doi:10.1016/j.ejpain.2006.02.013; Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000396. doi:10.1002/14651858.CD000396.pub3; Boudreault J, Desmeules F, Roy J, et al. The efficacy of oral nonsteroidal anti-inflammatory drugs for rotator cuff tendinopathy: a systematic review and meta-analysis. J Rehabil Med. 2014 Apr;46(4):294-306. doi:10.2340/16501977-1800; Moore R, Derry S, McQuay H. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Res Ther. 2008;10(3):R53. doi:10.1186/ar2422; Furst D, Kolba K, Fleischmann R, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002;29(3):436-46.; Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 22;10:CD004233. doi:10.1002/14651858. CD004233.pub4.; Yakhno N, Guekht A, Skoromets A, et al. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium. Clin Drug Invest. 2006;26(5):267-77. doi:10.2165/00044011-200626050-00004; Dougados M, Le Henanff A, Logeart I, Ravaud P. Short-term efficacy of rofecoxib and diclofenac in acute shoulder pain: a placebo-controlled randomized trial. PLoS Clin Trials. 2007 Mar 9;2(3):e9. doi:10.1371/journal.pctr.0020009; Chandanwale AS, Sundar S, Latchoumibady K, et al. Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study. J Pain Res. 2014 Aug 12;7:455-63. doi:10.2147/JPR.S67817. eCollection 2014.; Tramer MR, Williams JE, Carroll D, et al. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998 Jan;42(1):71-9. doi:10.1111/j.1399-6576.1998.tb05083.x; Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs. 2011;71(10):1259-79. doi:10.2165/11592550-000000000-00000; Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic muscoloskeletal pain in adults. Cochrane Database Sys Rev. 2012 Sep 12;9:CD 007400.; Baraf H, Gloth F, Barthel H, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, doubleblind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging. 2011;28(1):27-40. doi:10.2165/11584880-000000000-00000; Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi:10.2147/DHPS.S71976. eCollection 2015.; Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi:10.18433/J3VW2F; Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi:10.1186/ar4134; Day R, Graham G, Whelton A. The position of paracetamol in the world of analgesics. Am J Therap. 2000;7:51-5. doi:10.1097/00045391-200007020-00002; Prescott L. Paracetamol: past, present and future. Am J Ther. 2000;7:135-43. doi:10.1097/00045391-200007020-00011 113. Towheed T, Maxwell L, Judd M, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;25(1):CD004257. doi:10.1002/14651858.cd004257.pub2; Machado G, Maher C, Ferreira P, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. Brit Med J. 2015 Mar 31;350:h1225. doi:10.1136/bmj.h1225; Garcia Rodriguez L, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12(5):570-6. doi:10.1097/00001648-200109000-00018; Chan A, Manson J, Albert C, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578-87. doi:10.1161/CIRCULATIONAHA.105.595793; Dedier J, Stampfer M, Hankinson S, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40(5):604-8. doi:10.1161/01.HYP.0000035856.77718.DA; Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167(4):394-9. doi:10.1001/archinte.167.4.394; Ong C, Seymour R, Lirk P, Merry A. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010,110(4):1170-9. doi:10.1213/ane.0b013e3181cf9281; McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol Suppl. 2003;28:19-22.; Bronstein A, Spyker D, Cantilena L, et al. 2006 Annual Report of the American Association of Poison Control Centers National Poison Data System (NPDS). Clin Toxicol (Phila). 2007;45:815-917. doi:10.1080/15563650701754763; Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976). 2014 Apr 1;39(7):556-63. doi:10.1097/BRS.0000000000000249; Cepeda M, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol. 2007,34(3):543-55.; Da Costa BR, Nü esch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014 Sep 17;9:CD003115. doi:10.1002/14651858.cd003115.pub4; Metscher B, Kü bler U, Jahnel-Kracht H. Dexketoprofentrometamol and tramadol in acute lumbago. Fortschr Med Orig. 2001;118(4):147-51.; Pavelka K, Peliskova Z, Stehlikova H, et al. Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig. 1998;16(6):421-9. doi:10.2165/00044011-199816060-00002; Adams E, Breiner S, Cicero T, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31(5):465-76. doi:10.1016/j.jpainsymman.2005.10.006; Ritvo J, Koonce R, Thurstone C, Causey HL 3rd. Tramadol dependence: treatment with buprenor-phine/naloxone. Am J Addict. 2007;16(1):67-8. doi:10.1080/10550490601080118; Trescot A, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;Opioids Special Issue 11:5-62.; Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252. doi:10.1002/14651858.cd004252; Гурак СВ, Парфенов ВА, Борисов КН. Мидокалм в комплексной терапии острой поясничной боли. Боль. 2006;(3):27-30 [Gurak SV, Parfenov VA, Borisov KN. Mydocalm in the treatment of acute low back pain. Bol’. 2006;(3):27-30 (In Russ.)].; Ходинка Л, Меилингер М, Сабо Ж, Залавари И. Лечение острой поясничной боли Мидокалмом. Результаты международного мультицентрового рандомизированного двойного-слепого плацебо-контролируемого клинического исследования. Русский медицинский журнал. 2003;(5):246-9 [Khodinka L, Meilinger M, Sabo Zh, Zalavari I. Treatment of acute low back pain Mydocalm. The results of an international, multicentre, randomized, double-blind, placebo-controlled clinical trial. Russkii Meditsinskii Zhurnal. 2003;(5):246-9 (In Russ.)].; Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996 Oct;67(2-3):417-25. doi:10.1016/0304-3959(96)03187-9; Кукушкин МЛ. Современный взгляд на механизм действия Мидокалма. Consilium medicum. 2013;15(2):89-94 [Kukushkin ML. Modern view of the mechanism of action Mydocalm. Consilium medicum. 2013;15(2):89-94. (In Russ.)].; Шарапова ЕП, Алексеева ЛИ, Зайцева ЕМ и др. Применение миорелаксантов в комплексной терапии остеоартроза. Consilium medicum. 2008;(2):30-2 [Sharapova EP, Alekseeva LI, Zaitseva EM, et al. The use of muscle relaxants in the treatment of osteoarthritis. Consilium Medicum. 2008;(2):30-2 (In Russ.)].; Berry H, Hutchinson D. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res. 1988;16(2):75-82.; Berry H, Hutchinson D. Tizanidine and ibuprofen in acute lowback pain: results of a double-blind multicentre study in general practice. J Int Med Res. 1988;16(2):83-91.; Sirdalud Ternilin Asia-Pacific Study group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasm. Curr Ther Res. 1998;59:13-22. doi:10.1016/S0011-393X(98)85019-4; Pareek A, Chandurkar N, Chandanwale A, et al. Aceclofenactizanidine in the treatment of acute low back pain: a doubleblind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J. 2009;18(12):1836-42. doi:10.1007/s00586-009-1019-4; Karol D, Muzyk A, Preud'homme X. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry. 2011;33(1):84.; Del Rosario M, Weachter R, Flaker G. Drug-induced QT prolongation and sudden death. Mol Med. 2010;107(1):53-8.; Kaddar N, Vigneault P, Pilote S, et al. Tizanidine (Zanaflex): A muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):102-9. doi:10.1177/1074248410395020. Epub 2011 Feb 11.; Publow S, Branam D. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. Am J Health Syst Pharm. 2010;67(19):1606-10. doi:10.2146/ajhp090657; Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs. 2010;24(10):867-81. doi:10.2165/11536230-000000000-00000; Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother. 2009;10(9):1495-500. doi:10.1517/14656560902988528; Harish S, Bhuvana K, Bengalorkar GM, Kumar TN. Flupirtine: Clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2012;28:172-7. doi:10.4103/0970-9185.94833; Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther. 2011;49(11):637-47. doi:10.5414/CP210000; Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin. 2012 Oct;28(10):1617-34. doi:10.1185/03007995.2012.726216; Данилов АБ, Николаева НС. Эффективность новой формы флупиртина® (Катадолона форте) в лечении острой боли в спине. Manage pain. 2013;(1):44-8 [Danilov AB, Nikolaeva NS. The effectiveness of a new form of flupirtina® (Katadolona fort) in the treatment of acute pain in the back. Manage Pain. 2013;(1):44-8 (In Russ.)].; Richards B, Whittle S, van der Heijde D, Buchbinder R. Efficacy and safety of neuromodulators in inflammatory arthritis: A Cochrane Systematic Review. J Rheumatol Suppl. 2012;90:28-33. doi:10.3899/jrheum.120339; Chappell A, Ossanna M, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain. 2009;146(3):253-60. doi:10.1016/j.pain.2009.06.024; Williamson O, Schroer M, Ruff D, et al. Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials. Clin Ther. 2014 Apr 1;36(4):544-51. doi:10.1016/j.clinthera.2014.02.009. Epub 2014 Mar 17.; Pergolizzi JV Jr, Raffa RB, Taylor R Jr, et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013 Mar;13(3):239-52. doi:10.1111/j.1533-2500.2012.00578.x. Epub 2012 Jun 21.; Giladi H, Choiniere M, Fitzcharles MA, et al. Pregabalin for chronic pain: does one medication fit all? Curr Med Res Opin. 2015 Jul;31(7):1403-11. doi:10.1185/03007995.2015.1040750. Epub 2015 May 11.; Sakai Y, Ito K, Hida T, et al. Pharmacological management of chronic low back pain in older patients: a randomized controlled trial of the effect of pregabalin and opioid administration. Eur Spine J. 2015 Jun;24(6):1309-17. doi:10.1007/s00586-015-3812-6. Epub 2015 Feb 15.; Romano CL, Romano D, Lacerenza M. Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review. Pain Res Treat. 2012;2012:154781. doi:10.1155/2012/154781. Epub 2012 Apr 26.; Ohtori S, Inoue G, Orita S, et al. Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med J. 2013 Sep;54(5):1253-8. doi:10.3349/ymj.2013.54.5.1253; Carmichael N, Katz J, Clarke H, et al. An intensive perioperative regimen of pregabalin and celecoxib reduces pain and improves physical function scores six weeks after total hip arthroplasty: a prospective randomized controlled trial. Pain Res Manag. 2013 May-Jun;18(3):127-32. doi:10.1155/2013/258714; Hameed F, Ihm J. Injectable medications for osteoarthritis. PM&R. 2012;4(5 Suppl):75-81. doi:10.1016/j.pmrj.2012.02.010; Habib G, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol. 2010;29(4):347-56. doi:10.1007/s10067-009-1357-y; Dean BJF, Lostis E, Oakley T, et al. Risks and benefits of glucocorticoid treatment for tendinopathy: A systematic review of the effects of local glucocorticoid on tendon. Semin Arthritis Rheum. 2014;43(4):570-6. doi:10.1016/j.semarthrit.2013.08.006; Tallia A, Cardone D. Diagnostic and therapeutic injection of the shoulder region. Am Fam Physician. 2003;67(6):1271-8.; Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi:10.1016/S0140-6736(10)61160-9. Epub 2010 Oct 21.; Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005328. doi:10.1002/14651858.cd005328.pub2; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 с. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations]. Moscow: GEOTAR-Media; 2010. 752 p.].; Peloso P, Gross A, Haines T, et al. Medicinal and injection therapies for mechanical neck disorders. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000319. doi:10.1002/14651858.cd000319.pub4; Staal JB, de Bie RA, de Vet HC, et al. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2009 Jan 1;34(1):49-59. doi:10.1097/BRS.0b013e3181909558; Chou R, Hashimoto R, Friedly J, et al. Pain Management Injection Therapies for Low Back Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.; Farooq M, Devitt A. Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons. Ir J Med Sci. 2005;174(1):26-32. doi:10.1007/BF03168515; Charalambous C, Tryfonidis M, Sadiq S, et al. Septic arthritis following intraarticular glucocorticoid injection of the knee – a survey of current practice regarding antiseptic technique used during intra-articular glucocorticoid injection of the knee. Clin Rheumatol. 2003;22:386-90. doi:10.1007/s10067-003-0757-7; Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and nondiabetic patients. Joint Bone Spine. 2007 Oct;74(5):472-6. Epub 2007 Jul 6. doi:10.1016/j.jbspin.2006.10.009; Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intraarticular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014 May;93(5):372-8. doi:10.1097/PHM.0000000000000001; Strand V, McIntyre LF, Beach WR, et al. Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res. 2015 May 7;8:217-28. doi:10.2147/JPR.S83076. eCollection 2015.; Campbell KA, Erickson BJ, Saltzman BM, et al. Is local viscosupplementation injection clinically superior to other therapies in the treatment of osteoarthritis of the knee: A systematic review of overlapping meta-analyses. Arthroscopy. 2015 May 18. pii: S0749-8063(15)00257-1. doi:10.1016/j.arthro.2015.03.030 [Epub ahead of print].; Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Apr;43(5):593-9. doi:10.1016/j.semarthrit.2013.10.002. Epub 2013 Oct 14.; Colen S, Haverkamp D, Mulier M, van den Bekerom MP. Hyaluronic acid for the treatment of osteoarthritis in all joints except the knee: what is the current evidence? BioDrugs. 2012 Apr 1;26(2):101-12. doi:10.2165/11630830-000000000-00000; Lieberman JR, Engstrom SM, Solovyova O, et al. Is intra-articular hyaluronic acid effective in treating osteoarthritis of the hip joint? J Arthroplasty. 2015 Mar;30(3):507-11. doi:10.1016/j.arth.2013.10.019. Epub 2013 Nov 8.; Van den Bekerom MP, Lamme B, Sermon A, Mulier M. What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg. 2008 Aug;128(8):815-23. Epub 2007 Sep 15. doi:10.1007/s00402-007-0447-z; Blaine T, Moskowitz R, Udell J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am. 2008;90(5):970-9. doi:10.2106/JBJS.F.01116; Chang KV, Hsiao MY, Chen WS, et al. Effectiveness of intra-articular hyaluronic acid for ankle osteoarthritis treatment: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013 May;94(5):951-60. doi:10.1016/j.apmr.2012.10.030. Epub 2012 Nov 10.; Баринов АН, Пархоменко ЕВ, Махинов КА. Причины отрицательных исходов лечения боли в спине и способы их преодоления. Эффективная фармакотерапия. Неврология. 2014;49(5):40-50 [Barinov AN, Parkhomenko EV, Makhinov KA. The reasons for the negative outcomes of the treatment of back pain and how to overcome them. Effektivnaya farmakoterapiya. Nevrologiya. 2014;49(5):40-50 (In Russ.)].; Алексеева ЛИ. Препараты замедленного действия в лечении остеоартроза. Русский медицинский журнал. 2012;(7):389-94 [Alekseeva LI. Slow-acting drugs in the treatment of osteoarthritis. Russkii Meditsinskii Zhurnal. 2012;(7):389-94 (In Russ.)].; Imagawa K, de Andres M, Hashimoto K, et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes – implications for; osteoarthritis. Biochem Biophys Res Commun. 2011;405(3):362-7. doi:10.1016/j.bbrc.2011.01.007; Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4):R138. doi:10.1186/ar3077; Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition proinflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB. 2007;21(6):702-7.; Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi:10.1002/14651858.cd002946.pub2; Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90. doi:10.7326/0003-4819-146-8-200704170-00009; Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi:10.1002/14651858.cd005117.pub3; Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408. doi:10.1016/j.joca.2007.10.003; Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. ELAR, 2013, SAT0419; Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоартрозе). Научно-практическая ревматология. 2015;53(2):169-74 [Karateev AE, Alekseeva LI. Estimation of diacerein tolerability in real clinical practice: Results of the RACADA (Retrospective Assessment of Clinical Aspects of using Diaflex in osteoArthritis). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):169-74 (In Russ.)]. doi:10.14412/1995-4484-2015-169-174; Atchison J, Vincent HK. Obesity and low back pain: relationships and treatment. Pain Manag. 2012 Jan;2(1):79-86. doi:10.2217/pmt.11.64; Kotowski S, Davis KG. Influence of weight loss on musculoskeletal pain: Potential short-term relevance. Work. 2010;36(3):295-304. doi:10.3233/WOR-2010-1031; Wai EK, Rodriguez S, Dagenais S, Hall H. Evidence-informed management of chronic low back pain with physical activity, smoking cessation, and weight loss. Spine J. 2008 JanFeb;8(1):195-202. doi:10.1016/j.spinee.2007.10.024; Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007 Apr;66(4):433-9. doi:10.1136/ard.2006.065904. Epub 2007 Jan 4.; Gudbergsen H, Boesen M, Lohmander LS, et al. Weight loss is effective for symptomatic relief in obese subjects with knee osteoarthritis independently of joint damage severity assessed by high-field MRI and radiography. Osteoarthritis Cartilage. 2012 Jun;20(6):495-502. doi:10.1016/j.joca.2012.02.639. Epub 2012 Mar 5.; Jones A, Silva PG, Silva AC, et al. Impact of cane use on pain, function, general health and energy expenditure during gait in patients with knee osteoarthritis: a randomised controlled trial. Ann Rheum Dis. 2012 Feb;71(2):172-9. doi:10.1136/ard.2010.140178. Epub 2011 Nov 29.; Duivenvoorden T, Brouwer RW, van Raaij TM, et al. Braces and orthoses for treating osteoarthritis of the knee. Cochrane Database Syst Rev. 2015 Mar 16;3:CD004020. doi:10.1002/14651858.cd004020.pub3; Segal NA. Bracing and orthoses: a review of efficacy and mechanical effects for tibiofemoral osteoarthritis. PM&R. 2012 May;4(5 Suppl):S89-96. doi:10.1016/j.pmrj.2012.01.018; Raja K, Dewan N. Efficacy of knee braces and foot orthoses in conservative management of knee osteoarthritis: a systematic review. Am J Phys Med Rehabil. 2011 Mar;90(3):247-62. doi:10.1097/PHM.0b013e318206386b; Bennell KL, Buchbinder R, Hinman RS. Physical therapies in the management of osteoarthritis: current state of the evidence. Curr Opin Rheumatol. 2015 May;27(3):304-11. doi:10.1097/BOR.0000000000000160; Bervoets DC, Luijsterburg PA, Alessie JJ, et al. Massage therapy has short-term benefits for people with common musculoskeletal disorders compared to no treatment: a systematic review. J Physiother. 2015 Jul;61(3):106-16. doi:10.1016/j.jphys.2015.05.018. Epub 2015 Jun 17.; Kadhim-Saleh A, Maganti H, Ghert M, et al. Is low-level laser therapy in relieving neck pain effective? Systematic review and meta-analysis. Rheumatol Int. 2013 Oct;33(10):2493-501. doi:10.1007/s00296-013-2742-z. Epub 2013 Apr 12.; Brosseau L, Robinson V, Wells G, et al. WITHDRAWN: Low level laser therapy (Classes III) for treating osteoarthritis. Cochrane Database Syst Rev. 2007 Jul 18;(1):CD002046.; Pittler MH, Brown EM, Ernst E. Static magnets for reducing pain: systematic review and meta-analysis of randomized trials. CMAJ. 2007 Sep 25;177(7):736-42. doi:10.1503/cmaj.061344; Ryang We S, Koog YH, Jeong KI, Wi H. Effects of pulsed electromagnetic field on knee osteoarthritis: a systematic review. Rheumatology (Oxford). 2013 May;52(5):815-24. doi:10.1093/rheumatology/kes063. Epub 2012 Apr 13.; Li S, Yu B, Zhou D, et al. Electromagnetic fields for treating osteoarthritis. Cochrane Database Syst Rev. 2013 Dec 14;12:CD003523. doi:10.1002/14651858.cd003523.pub2; Menke JM. Do manual therapies help low back pain? A comparative effectiveness meta-analysis. Spine (Phila Pa 1976). 2014 Apr 1;39(7):E463-72. doi:10.1097/BRS.0000000000000230; Rubinstein SM, Terwee CB, Assendelft WJ, et al. Spinal manipulative therapy for acute low-back pain. Cochrane Database Syst Rev. 2012 Sep 12;9:CD008880. doi:10.1002/14651858.cd008880.pub2; Franke H, Franke JD, Fryer G. Osteopathic manipulative treatment for nonspecific low back pain: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2014 Aug 30;15:286. doi:10.1186/1471-2474-15-286; Lam M, Galvin R, Curry P. Effectiveness of acupuncture for nonspecific chronic low back pain: a systematic review and metaanalysis. Spine (Phila Pa 1976). 2013 Nov 15;38(24):2124-38. doi:10.1097/01.brs.0000435025.65564.b7; Xu M, Yan S, Yin X, et al. Acupuncture for chronic low back pain in long-term follow-up: a meta-analysis of 13 randomized controlled trials. Am J Chin Med. 2013;41(1):1-19. doi:10.1142/S0192415X13500018; Haake M, Mü ller H, Schade-Brittinger C, et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med. 2007;167(17):1892-8. doi:10.1001/Archinte.167.17.1892; Manheimer E, Cheng K, Linde K, et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001977. doi:10.1002/14651858.CD001977.pub2; Manyanga T, Froese M, Zarychanski R, et al. Pain management with acupuncture in osteoarthritis: a systematic review and metaanalysis. BMC Complement Altern Med. 2014 Aug 23;14:312. doi:10.1186/1472-6882-14-312; So P, Jiang Y, Qin Y. Touch therapies for pain relief in adults. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006535. doi:10.1002/14651858.cd006535.pub2; Smith K. Against homeopathy – a utilitarian perspective. Bioethics. 2012;26(8):398-409. doi:10.1111/j.1467-8519.2010.01876.x; Brien S, Lachance L, Prescott P, et al. Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. Rheumatology (Oxford). 2011;50(6):1070-82. doi:10.1093/rheumatology/keq234; Beer A, Fey S, Zimmer M, et al. Effectiveness and safety of homeopathic drug combination in the treatment of chronic low back pain. A double-blind, randomized, placebo-controlled clinical trial. MMW Fortschr Med. 2012 Jun 28;154 Suppl 2:48-57.; Long L, Ernst E. Homeopathic remedies for the treatment of osteoarthritis: a systematic review. Br Homeopath J. 2001 Jan;90(1):37-43. doi:10.1054/homp.1999.0449; Koley M, Saha S, Ghosh S. A double-blind, randomized, placebo-controlled feasibility study evaluating individualized homeopathy in managing pain of knee osteoarthritis. J Evid Based Complement Altern Med. 2015 Jul;20(3):186-91. doi:10.1177/2156587214568668; Lembeck M. Quantum physics, medicine and insurance. Versicherungsmedizin. 2007;59(4):179-85.; Jain S, Mills P. Biofield therapies: helpful or full of hype? A best evidence synthesis. Int J Behav Med. 2010;17(1):1-16. doi:10.1007/s12529-009-9062-4; Rosch P. Bioelectromagnetic and subtle energy medicine: the interface between mind and matter. Ann N Y Acad Sci. 2009;1172:297-311. doi:10.1111/j.1749-6632.2009.04535.x; Galle M. Bioresonance, a study of pseudo-scientific language. Forsch Komplementarmed Klass Naturheilkd. 2004;11(5):306.; Hammerschlag R, Marx B, Aickin M. Nontouch biofield therapy: a systematic review of human randomized controlled trials reporting use of only nonphysical contact treatment. J Altern Compliment Med. 2014 Dec;20(12):881-92. doi:10.1089/acm.2014.0017; https://rsp.mediar-press.net/rsp/article/view/2206

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2206
https://doi.org/10.14412/1995-4484-2016-247-265

المؤلفون: S. KOPENKIN S., С. КОПЁНКИН С.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2016); 143-147 ; Медицинский Совет; № 10 (2016); 143-147 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-10

مصطلحات موضوعية: venous thromboembolic complications, prevention in traumatology and orthopedics, low-molecular heparins, sodium bemiparin, венозные тромбоэмболические осложнения, предупреждение в травматологии и ортопедии, низкомолекулярные гепарины, бемипарин натрия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1418/1376; Geerts W, Pineo G, Heit J et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126: 338-400.; Матвеева Н.Ю., Еськин Н.А., Нацвлишвили З.Г. Тромбозы глубоких вен нижних конечностей у больных, перенесших эндопротезирование тазобедренного сустава. Вестник травматологии и ортопедии, 2002, 2: 54-57. / Matveeva N.Y., Eskin N.A., Natsvlishvili Z.G. Thromboses of lower extremities deep veins in patients after hip replacement. Vestnik travmatologii i ortopedii, 2002, 2: 54-57.; Скороглядов А.В., Копенкин С.С. Профилактика тромбоэмболических осложнений у травматологических больных в остром периоде травмы. В сб. Профилактика тромбоэмболических осложнений в травматологии и ортопедии. М. 2003: 18-33. / Skoroglyadov A.V., Kopenkin S.S. Prevention of thromboembolic complications in traumatology patients in acute trauma period. In coll. Prevention of thromboembolic complications in traumatology and orthopedy. M. 2003: 18-33.; Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии: Российские клиническиерекомендации. Травматология и ортопедия России, 2012, Приложение 1: 2-24. / Prevention of venous thromboembolic complications in traumatology and orthopedics: Russian clinical recommendations. Travmatologiya i ortopedia Rossii, 2012, Appendix 1: 2-24.; Бутров А.В., Кондрашенко Е.Н., Бут-Гусаим А.Б. Применение препарата Цибор для профилактики тромбоэмболических осложнений при эндопротезировании крупных суставов. Consilium Medicum/Хирургия, 2011, 2: 38-40. / Butrov A.V., Kondrashenko E.N., But- Gusaim A.B. Application of Zibor for prevention of thromboembolic complications in arthroplasty of large joints. Consilium Medicum/Khirurgia, 2011, 2: 38-40.; Адаптировано из Planes A. Expert Opin. Pharmacother, 2003, 4(9): 1551-1561. / Adapted from Planes A. Expert Opin. Pharmacother, 2003, 4 (9): 1551-1561.; Инструкции по медицинскому применению препаратов Цибор®2500 и Цибор®3500./Patient Leaflet Information for Zibor®2500 and Zibor®3500.; https://www.med-sovet.pro/jour/article/view/1418

الاتاحة: https://www.med-sovet.pro/jour/article/view/1418
https://doi.org/10.21518/2079-701X-2016-10-143-147